Interleukin-28 and hepatitis C virus genotype-4: Treatment-induced clearance and liver fibrosis

Table 1 Demographic and clinical characteristics of the study participants

	End of treatment response		Sustained viral response
	No	Yes	No	Yes
Age, median (IQR)	48.0 (40.5-53.0)	46.0 (40.0-51.0)	48.0 (43.5-53.0)	46.0 (38.0-51.0)
HCV log10 viral load, median (IQR)	5.9 (5.1-6.4)	5.5 (3.8-6.3)	5.8 (5.2-6.5)	5.4 (3.6-6.1)
Male (%)	93.1	87.5	91.3	88.1
rs12979860 (%)
TT	30.0	5.1	23.3	7.6
CT	52.9	47.0	53.4	45.2
CC	17.1	47.9	23.3	47.2

HCV: Hepatitis C virus; IQR: Inter-quartile range.

Table 2 Adjusted associations between interleukin-28B genotype and response to treatment

	End of treatment response		Sustained viral response
	OR (95%CI)	P value	OR (95%CI)	P value
rs12979860
TT	Ref. genotype		Ref. genotype
CT	5.15 (1.80-14.78)	0.002	2.48 (0.94-6.52)	0.065
CC	17.55 (5.34-57.69)	< 0.0001	5.92 (2.09-16.76)	< 0.001

OR: Odds ratio.